Cyteir Therapeutics, Inc. Common Stock
CYT
CYT was delisted on the 15th of March, 2024.
30 hedge funds and large institutions have $28.5M invested in Cyteir Therapeutics, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 12 reducing their positions, and 10 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
18% less capital invested
Capital invested by funds: $34.6M → $28.5M (-$6.11M)
19% less funds holding
Funds holding: 37 → 30 (-7)
42% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 12
60% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NM
Newtyn Management
New York
|
+$587K |
| 2 |
Millennium Management
New York
|
+$96.5K |
| 3 |
E
Ergoteles
New York
|
+$48.4K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$33.8K |
| 5 |
IAIM
International Assets Investment Management
Orlando,
Florida
|
+$23.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$927K |
| 2 |
CCM
CAAS Capital Management
New York
|
-$252K |
| 3 |
BBA
Baker Bros. Advisors
New York
|
-$243K |
| 4 |
BlackRock
New York
|
-$189K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$67K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LC
26
Lindbrook Capital
Calabasas,
California
| $3.31K | – | – | – |
|
27
JP Morgan Chase
New York
| $1K | -$2.46K | -1,536 | -76% |
|
28
Citigroup
New York
| $406 | -$679 | -423 | -63% |
|
29
Wells Fargo
San Francisco,
California
| $160 | +$5 | +3 | +3% |
|
|
30
UBS Group
Zurich,
Switzerland
| – | -$67K | -34,809 | Closed |
|
31
Two Sigma Investments
New York
| – | -$25K | -13,093 | Closed |
|
32
Mariner
Overland Park,
Kansas
| – | -$23K | -11,852 | Closed |
|
33
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$23K | -11,796 | Closed |
|
34
Goldman Sachs
New York
| – | -$22K | -11,670 | Closed |
|
|
TRCT
35
Tower Research Capital (TRC)
New York
| – | -$11K | -5,859 | Closed |
|
|
SPIA
36
Steward Partners Investment Advisory
New York
| – | -$4K | -2,200 | Closed |
|
|
PA
37
Parallel Advisors
San Francisco,
California
| – | -$1K | -464 | Closed |
|
|
CUAMC
38
China Universal Asset Management Company
Shanghai,
China
| – | -$1K | -332 | Closed |
|
39
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$5 | +3 | New |
|
CYT Hedge Fund Activity: Q4 2022 in Review
30 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Cyteir Therapeutics, Inc. Common Stock (CYT) for Q4 2022, worth a combined $28.5M — down 18% from $34.6M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of CYT and 4 opened new positions — a net loss of 6 holders — while 12 trimmed existing stakes and 7 added.
The largest buyer was Newtyn Management, adding an estimated $587K. The largest seller was Fidelity Investments, cutting an estimated $927K.
- 30 institutional investors held Cyteir Therapeutics, Inc. Common Stock (CYT) as of Q4 2022, down from 37 in Q3 2022.
- Funds reported $28.5M of Cyteir Therapeutics, Inc. Common Stock stock for Q4 2022, down 18% quarter-over-quarter.
- 4 funds opened new Cyteir Therapeutics, Inc. Common Stock positions in Q4 2022 and 10 closed out, a net change of -6 holders.
- The largest Cyteir Therapeutics, Inc. Common Stock buyer in Q4 2022 was Newtyn Management, an estimated $587K added.
- The largest Cyteir Therapeutics, Inc. Common Stock seller in Q4 2022 was Fidelity Investments, an estimated $927K sold.
Based on aggregated 13F filings for Q4 2022.